Pfizer Stock Hits a High After President Biden Screams “We Beat Pharma!”

In early September, the sitting president of the United States yelled, “we beat Pharma this year!” during a Labor Day speech in Milwaukee. This announcement comes after the Biden administration enabled the pharmaceutical industry to profit billions in dollars by (until recently) enforcing “vaccine” mandates on federal employees and contractors.

Once again, Joe Biden, the appointed 46th president belted out during a speech in Pittsburgh: “I have been fighting Pharma for my entire career, my entire career, and we finally beat Pharma!”

Biden, who accepted $1 million from pharmaceutical giant Pfizer Inc. for his inauguration, now claims “we finally beat Pharma.” In an attempt to read between the lines, we might want to note that Pfizer reported a record-high sales of $27.7 billion for the second quarter in late July—that’s an increase of 47 percent from the same period last year—by driving the COVID “vaccine” and antiviral drug Paxlovid.

Now let’s not forget that during this year’s State of the Union address, Biden called on Congress to give the federal health insurance program, Medicare, the authority to negotiate lowering drug prescription prices, as mentioned in the $1.8 trillion American Families Plan FACT-SHEET published by the White House in April 2021.

And then there’s the Ensuring Innovation Act, a law passed through the Senate with unanimous, bipartisan support. It was developed to help prevent pharmaceutical manufacturers from making minor adjustments to raise drug prices, and support generic and biosimilar drugs instead of branded drugs.

A bill of higher implication for the pharmaceutical industry might be The Inflation Reduction Act, which was signed into law in mid-August. It now allows the U.S. government to negotiate prices on prescription drugs and place a cap at $2,000 per year for people on the Medicare program.

But all in all, it’s hard to imagine Big Pharma’s lobbying efforts diminishing. Indeed, according to a STAT analysis, “seventy-two senators and 302 members of the House of Representatives cashed a check from the pharmaceutical industry ahead of the 2020 election.” Such donations were divided between the Democratic and Republican party, with the former receiving $6.6 million and the latter obtaining $7.1 million.

Less than a day after the 46th president screamed “we beat Pharma” in multiple speeches on Labor Day, Pfizer’s stock price spiked. A leading authoritative source for stock market information, Stocks Register, reported that:

Pfizer Inc. (NYSE:PFE) price is hovering higher on Tuesday, September 06, jumping 0.61% above its previous close…Staying with the analyst view, there is a consensus estimate of $100.41 billion for the company’s annual revenue in 2022. Per this projection, the revenue is forecast to grow 23.50% above that which the company brought in 2022.

Indeed, Biden’s announcement is bewildering, given the current administration’s efforts to inject nearly every American with the COVID “vaccines” developed by pharmaceutical giants Pfizer, Moderna, Inc. and Johnson & Johnson (J&J).

For instance, Moderna reportedly earned $12.2 billion net income in 2021, with the majority of this total driven by the COVID “vaccine” or “shot” production. According to the company’s report released in late February:

Total revenue was $18.5 billion for the full year 2021, compared to $803 million in 2020. Total revenue increased in 2021, primarily due to commercial sales of the Company’s COVID-19 vaccine. Product sales for the full year 2021 were $17.7 billion from sales of 807 million doses of the Company’s COVID-19 vaccine.

A Bloomberg analysis released in April showed that J&J’s Janssen sales for its COVID shots amounted to $23.4 billion, “narrowly missing the average estimate.” It adds that J&J maintained its “operational profit and sales forecast and boosted its quarterly dividend to $1.13 a share from $1.06.”

In fact, J&J’s Chief Financial Officer, Joseph Wolk, said that he hopes that suspending the 2022 “vaccine guidance” for the sales of its COVID shots will convince investors that the company’s COVID-related production isn’t central to the business.

So, business keeps chugging ahead. New infections. New diseases. New needs. New inoculations. How can such a business model fail to reproduce and reinvent itself?

Perhaps Biden can clarify what he meant by “we beat Pharma.”

The United States continues to reign as having some of the biggest pharmaceutical companies worldwide. In 2021 alone, the total amount spent on medicines in the U.S. reportedly reached approximately $574 billion. While Pfizer’s total revenue was $81.3 billion, another U.S. pharmaceutical company, Merck & Co., Inc., achieved a more modest total revenue of $48.7 billion.

On a different note, the United States is also leading in pharmaceutical expenditure compared to other nations that are part of the Organization for Economic Co-operation and Development (OECD).

According to an article published by Statista, a company specializing in consumer data, Americans spent, on average, up to $1,376 worth of medications in 2019. This cost is still 47 percent higher than its biggest spending competitor, Germany.

On insurance, the article continues to add:

Government and government-mandated insurance covered 55 percent of total pharmaceutical spending across OECD nations, with the share as high as 80 percent in Germany and France. That number was 70 percent in the United States.

If that weren’t enough, U.S. pharmaceutical giants are projected to make the following 2022 sales, starting with Pfizer at a swooping $67.4 billion, followed by blazing AbbVie ($58.4 billion), J&J ($55.2 billion), and of course, more modest earnings by Bristol-Myers Squibb ($49.1 billion) and Merck & Co. ($45.1 billion).

So yes, Biden should really clarify what he meant by “we beat Pharma.”

In mid-October 2021, investigative journalist Whitney Webb tweeted a compilation video highlighting several mainstream U.S. news channels such as CNN, CNBC, NBC and ABC as being sponsored by—Pfizer. In addition to Fox News, all these channels have pushed for Americans to receive the COVID shots, and the likes of CNN have even expressed support for mandates.

Just a few examples:

• CNBC tweeted a news article praising Pfizer for its technological achievements concerning the COVID mRNA shots. However, at the end of the tweet, the caption reads, “Paid Post for @pfizer.”

• A television skit delivered by late-night show host Jimmy Kimmel on the mRNA shots was sponsored by “@Moderna_tx #SponsoredByModerna.”

By funding entertainment and news programs, Big Pharma might have more intentions than simply increasing mass inoculation rates. But while the pharmaceutical industry pays mainstream news networks to receive favorable coverage for its products, it’s a very different case for those who have tried to raise awareness about potential “vaccine” injuries.

Consider the case of teenager Maddie de Garay, who experienced severe symptoms after receiving the second dose of the Pfizer-BioNTech shot in a trial.

By October 2021, the Vaccine Safety Research Association had prepared an advertisement to raise awareness about de Garay’s injuries. It was initially accepted for broadcast by Comcast telecommunications conglomerate and was scheduled to air during the Saturday Night Live broadcast, and Meet the Press. But the 30-second video featuring de Gray was pulled just a day after its approval.

At this stage, is it surprising to learn that Comcast is the owner of NBCUniversal Media, L.L.C., which just so happens to be the parent company of NBC and CNBC?

Come again, President Biden?

Content syndicated from Dear Rest of America with permission